Penetration of micafungin into the burn eschar in patients with severe burns
- PMID: 23771854
- DOI: 10.1007/s13318-013-0146-9
Penetration of micafungin into the burn eschar in patients with severe burns
Abstract
Micafungin (MCFG) concentrations in the plasma and in burn eschar were investigated after daily intravenous infusion (1 h) of MCFG (200 mg) in three patients with severe burns. MCFG treatment was initiated more than 72 h after the burn injuries. The MCFG concentrations in the plasma were determined at the end of the first administration of MCFG, immediately before the second dosing, at the end of the MCFG infusion after at least 4 days from the initial treatment, and immediately before the subsequent dosing using high-performance liquid chromatography. In addition, the trough levels in burn eschar after both the initial administration and repeated administration were measured. The peak and trough levels in the plasma were comparable to or slightly lower than the reported values in healthy volunteers. The mean (range) MCFG concentrations in the burn eschar after initial administration and repeated administration were 1.41 μg/mL (<0.1-3.98 μg/mL) and 6.65 μg/mL (1.10-14.81 μg/mL), respectively. In most cases, the MCFG concentrations in the burn eschar, especially after repeated administration, were higher than the reported MIC90 of MCFG against the clinically important pathogenic species of Candida and Aspergillus. These results suggest that MCFG is capable of penetrating burn eschar.
Similar articles
-
Micafungin concentrations in the plasma and burn eschar of severely burned patients.Antimicrob Agents Chemother. 2012 Feb;56(2):1113-5. doi: 10.1128/AAC.05381-11. Epub 2011 Nov 14. Antimicrob Agents Chemother. 2012. PMID: 22083486 Free PMC article.
-
Effect of liver and kidney function on migafungin disposition in patients with hematologic malignancies.Eur J Drug Metab Pharmacokinet. 2008 Jul-Sep;33(3):191-8. doi: 10.1007/BF03191118. Eur J Drug Metab Pharmacokinet. 2008. PMID: 19007046
-
Safety, tolerability, and feasibility of antifungal prophylaxis with micafungin at 2 mg/kg daily in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.Infection. 2014 Aug;42(4):639-47. doi: 10.1007/s15010-014-0601-9. Epub 2014 Feb 25. Infection. 2014. PMID: 24567233
-
[Antifungal activity and clinical efficacy of micafungin (funguard)].Nihon Ishinkin Gakkai Zasshi. 2005;46(4):217-22. doi: 10.3314/jjmm.46.217. Nihon Ishinkin Gakkai Zasshi. 2005. PMID: 16282962 Review. Japanese.
-
Echinocandin antifungal drugs in fungal infections: a comparison.Drugs. 2011 Jan 1;71(1):11-41. doi: 10.2165/11585270-000000000-00000. Drugs. 2011. PMID: 21175238 Review.
Cited by
-
Comparative Population Plasma and Tissue Pharmacokinetics of Micafungin in Critically Ill Patients with Severe Burn Injuries and Patients with Complicated Intra-Abdominal Infection.Antimicrob Agents Chemother. 2016 Sep 23;60(10):5914-21. doi: 10.1128/AAC.00727-16. Print 2016 Oct. Antimicrob Agents Chemother. 2016. PMID: 27458229 Free PMC article. Clinical Trial.
-
Infections fongiques des brûlé : revue.Ann Burns Fire Disasters. 2015 Mar 31;28(1):21-8. Ann Burns Fire Disasters. 2015. PMID: 26668558 Free PMC article. French.
-
Penetration of echinocandins into wound secretion of critically ill patients.Infection. 2021 Aug;49(4):747-755. doi: 10.1007/s15010-021-01604-x. Epub 2021 Apr 20. Infection. 2021. PMID: 33877638 Free PMC article.
-
Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.Infection. 2017 Dec;45(6):737-779. doi: 10.1007/s15010-017-1042-z. Epub 2017 Jul 12. Infection. 2017. PMID: 28702763 Free PMC article. Review.
-
Clinical Pharmacokinetics and Pharmacodynamics of Micafungin.Clin Pharmacokinet. 2018 Mar;57(3):267-286. doi: 10.1007/s40262-017-0578-5. Clin Pharmacokinet. 2018. PMID: 28791666 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical